All In Biotech

Drug Trial Radar · NCT00088504

Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C

A Phase 2b Study of Merimepodib in Combination With Pegylated Interferon Alfa-2a (Pegasys®) and Ribavirin in Subjects With Chronic Hepatitis C Non-Responsive to Prior Therapy With Pegylated Interferon Alfa and Ribavirin

Last checked: Nov 20, 2026Latest source record: Dec 21, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 315 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

315

Actual

Start

Jul 2004

Primary completion

Not stated

Study completion Oct 2006

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Jul 28, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is designed to test whether or not the addition of merimepodib (MMPD) to the standard therapy of pegylated interferon and ribavirin will result in a positive treatment response for people who have not previously responded to this therapy. Approximately 315 subjects will be enrolled in this research study at approximately 55 clinical sites in the United States. There will be three study groups. Everyone in the study will receive Pegasys® (pegylated interferon) and Copegus® (ribavirin) at the normally prescribed doses. Two of the groups will also receive the study drug merimepodib (MMPD) twice a day, one group at each dose level being tested. The third group will take a placebo instead of MMPD, with the Pegasys® and Copegus®. After the first 24 weeks of treatment, blood tests will be done to see if subjects are responding to treatment. If they are responding, they will continue receiving study treatment in the study for another 24 weeks. If they are not responding, they will stop study treatment. Everyone who is responding will be monitored for 24 weeks after the last dose of medication, to see how long the response lasts. Evaluations will be performed during the study to look at the safety of the Pegasys®/Copegus® and MMPD or placebo combination, and to see how the combination is working by measuring Hepatitis C Virus in the blood. At some of the clinical sites performing the study, some subjects may also participate in additional testing to look at the metabolism of the drugs, or to look at the immune response to Hepatitis C virus infection and treatment.

Conditions

  • Hepatitis C
  • Hepatitis

Interventions

  • MerimepodibDrug

  • PEG-Interferon-alpha 2a (Pegasys®)Drug

  • Ribavirin (Copegus®)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

67 sites in 1 country. Site status is shown where the registry gives one.

  • Joseph L. Cochran, M.D.

    Birmingham, Alabama

  • Suresh Karne, M.D., Ph.D.

    Huntsville, Alabama

  • Vijayan Balan, M.D.

    Phoenix, Arizona

  • Michael P. DeMicco, M.D.

    Anaheim, California

  • Prahalad B. Jajodia, M.D.

    Fresno, California

  • F. Fred Poordad, M.D.

    Los Angeles, California

  • Ramsey Cheung, M.D.

    Palo Alto, California

  • Myron J. Tong, M.D., Ph.D.

    Pasadena, California

  • Michael T. Bennett, M.D.

    San Diego, California

  • Lisa M. Nyberg, M.D.

    San Diego, California

  • Natalie Bzowej, M.D.

    San Francisco, California

  • Marcelo Kugelmas, M.D.

    Englewood, Colorado

  • Herbert L. Bonkovsky, M.D.

    Farmington, Connecticut

  • Eugene R. Schiff, M.D.

    Miami, Florida

  • Jawahar L. Taunk, M.D.

    Palm Harbor, Florida

  • Arnold L. Lentnek, M.D.

    Marietta, Georgia

  • Ellen B. Hunter, M.D.

    Boise, Idaho

  • Steven L. Flamm, M.D.

    Chicago, Illinois

  • Helen Te, M.D.

    Chicago, Illinois

  • Gerald J. Mingoletti, M.D.

    Oak Forest, Illinois

  • Donald R. Graham, M.D.

    Springfield, Illinois

  • Alvaro G. Koch, M.D.

    Lexington, Kentucky

  • Shaban Faruqui, M.D.

    Baton Rouge, Louisiana

  • Robert M. Be, M.D.

    Baton Rouge, Louisiana

  • Bal Raj Bhandari, M.D.

    Monroe, Louisiana

  • Luis A. Balart, M.D.

    New Orleans, Louisiana

  • Robert Perrillo, M.D.

    New Orleans, Louisiana

  • Michael Epstein, M.D.

    Annapolis, Maryland

  • Natarajan Ravendhran, M.D.

    Baltimore, Maryland

  • Mark Sulkowski, M.D.

    Baltimore, Maryland

  • Milton J. Koch, M.D.

    Silver Spring, Maryland

  • David N. Schwartz, M.D.

    Attleboro, Massachusetts

  • Nezam Afdhal, M.D.

    Boston, Massachusetts

  • Lawton Shick, M.D.

    Worcester, Massachusetts

  • Stuart C. Gordon, M.D.

    Detroit, Michigan

  • John B. Gross, M.D.

    Rochester, Minnesota

  • Jeffrey Rank, M.D.

    Saint Paul, Minnesota

  • Adrian Di Bisceglie, M.D.

    St Louis, Missouri

  • William C. Sloan

    Florham Park, New Jersey

  • Rajendra Prasad Gupta, M.D.

    Trenton, New Jersey

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.